TABLE 5. Changes From Baseline for SCr and eGFR
Iopamidol-370 Group | Iodixanol-320 Group | P* | |||
---|---|---|---|---|---|
N | Mean Change±SD | N | Mean Change±SD | ||
*P value for comparison of contrast agent groups based on ANCOVA model. | |||||
Total population | |||||
SCr, mg/dL | 204 | 0.07±0.22 | 210 | 0.12±0.23 | 0.032 |
eGFR, mL/min per 1.73 m2 | 204 | −2.16±7.86 | 210 | −4.02±8.10 | 0.038 |
Patients without diabetes mellitus | |||||
SCr, mg/dL | 126 | 0.07±0.19 | 118 | 0.08±0.18 | 0.708 |
eGFR, mL/min per 1.73 m2 | 126 | −2.23±7.18 | 118 | −3.28±8.35 | 0.695 |
Patients with diabetes mellitus | |||||
SCr, mg/dL | 78 | 0.07±0.26 | 92 | 0.16±0.27 | 0.013 |
eGFR, mL/min per 1.73 m2 | 78 | −2.05±8.90 | 92 | −4.97±7.65 | 0.016 |